We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 11-20 of 1,234

Court grants motion to reopen trial and admit new evidence
  • Borden Ladner Gervais LLP
  • Canada
  • April 27 2011

The Federal Court granted leave to reopen the trial and admit new evidence in a matter under reserve, in which no reasons or judgement have issued

TPP: new rights for pharmaceutical patent holders
  • Gowling WLG
  • Canada
  • December 9 2015

On November 5 2015 the Canadian government released the official consolidated text of the Trans-Pacific Partnership (TPP). This follows the technical

Canadian Competition Bureau Releases Significant Updates to its IP Enforcement Guidelines
  • McCarthy Tétrault LLP
  • Canada
  • April 7 2016

On March 31, 2016, the Competition Bureau (Bureau) released revised Intellectual Property Enforcement Guidelines (IPEGs). These IPEGs reflect

Leave to Appeal to SCC: AstraZeneca Canada Inc et al v Apotex Inc et al (FCCA)
  • Bereskin & Parr LLP
  • Canada
  • March 10 2016

On March 10, 2016, the Supreme Court of Canada granted AstraZeneca Canada Inc.'s ("AstraZeneca") application for leave to appeal from the decision of

Canadian patent judge takes a hard stand against generic CIALIS (tadalafil)
  • McCarthy Tétrault LLP
  • Canada
  • January 26 2015

On January 7, 2015, Justice de Montigny of the Federal Court released his judgment and reasons in Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC

Federal Court of Appeal clarifies misunderstanding: factual basis and line of reasoning need not be disclosed in the patent
  • McCarthy Tétrault LLP
  • Canada
  • June 8 2015

In a decision released on June 3, 2015 (2015 FCA 137), a unanimous Federal Court of Appeal (“FCA”) dismissed Apotex’s appeal of Justice O’Reilly’s

Biosimilar battlegrounds - what is new in biosimilars and where?
  • Bereskin & Parr LLP
  • Canada, European Union, USA
  • February 17 2012

Biosimilars are second entry biologic drugs

Methods of medical treatment and dosage claims
  • Gowling WLG
  • Canada
  • June 28 2011

In Canada, claims to methods of medical treatment are considered to fall outside the definition of invention according to section 2 of the Patent Act and a decision of the Supreme Court of Canada

How much disclosure is required to support utility of a patented drug?
  • Fasken Martineau DuMoulin LLP
  • Canada
  • May 2 2012

The Federal Court of Canada has held that Sanofi-Aventis Patent 1,336,777 for clopidogrel bisulfate (Plavix) was infringed by Apotex, but was invalid on the basis of lack of utility

Federal Court of Appeal considers standard for “obvious to try” test
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • January 19 2016

On December 15, 2015, the Federal Court of Appeal confirmed that the correct standard for determining whether an invention is obvious under the